Glycans flanking the hypervariable connecting peptide between the a and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01-AE viruses

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  O'Rourke, Sara M ^a   Sutthent, Ruengpung ^b   Phung, Pham ^c   Mesa, Kathryn A ^a   Frigon, Normand L ^a   To, Briana ^a   Horthongkham, Navin ^b   Limoli, Kay ^c   Wrin, Terri ^c   Berman, Phillip W ^a,d  

^a University of California Santa Cruz   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MONOGRAM BIOSCIENCES   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE; RECOMBINANT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; POLYSACCHARIDE; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLADISTICS; CONTROLLED STUDY; DRUG RESEARCH; ENVELOPE GENE; GENE LIBRARY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS CHARACTERIZATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; DRUG USE; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SERODIAGNOSIS; VIROLOGY;

AVIAN ENCEPHALOMYELITIS VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; DRUG USERS; GENOTYPE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; PEPTIDES; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; SEQUENCE ALIGNMENT;

EID: 84925967803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119608     Document Type: Article

References (68)

1. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83: 188-199. doi: 10.1128/JVI.01583-08 PMID: 18922865
2. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81: 6548-6562. PMID: 17409160
3. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83: 757-769. doi: 10.1128/JVI.02036-08 PMID: 18987148
4. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011; 85: 11502-11519. doi: 10.1128/JVI.05363-11 PMID: 21849452
5. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13: 1032-1034. PMID: 17721546
6. Binley J. Specificities of broadly neutralizing anti-HIV-1 sera. Curr Opin HIV AIDS 2009; 4: 364-372. doi: 10.1097/COH.0b013e32832e06fe PMID: 20048699
7. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100: 4144-4149. PMID: 12644702
8. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312. PMID: 12646921
9. Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis 2010; 202: 657-666. doi:10.1086/655397 PMID: 20649427
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199. PMID: 10392984
11. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-285. doi: 10.1086/589297 PMID: 18549313
12. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394. PMID: 12167680
13. O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, et al. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutrali-zation-resistant virus. J Virol 2010; 84: 11200-11209. doi: 10.1128/JVI.00790-10 PMID: 20702624
14. O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, Sinangil F, et al. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol 2009; 83: 7728-7738. doi: 10.1128/JVI.00688-09 PMID: 19474108
15. O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, et al. Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. J Virol 2012; 86: 12105-12114. doi: 10.1128/JVI.01352-12 PMID: 22933284
16. Perez-Losada M, Jobes DV, Sinangil F, Crandall KA, Arenas M, Posada D, et al. Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. PLoS One 2011; 6: e16902. doi: 10. 1371/journal.pone.0016902 PMID: 21423744
17. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1484-1490. doi: 10.1126/science.1245627 PMID: 24179160
18. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1477-1483. doi: 10.1126/science.1245625 PMID: 24179159
19. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 2013; 110: 4351-4356. doi: 10.1073/pnas.1217537110 PMID: 23426631
20. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/ V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480: 336-343. doi: 10.1038/ nature10696 PMID: 22113616
21. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334: 1097-1103. doi: 10. 1126/science.1213256 PMID: 21998254
22. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. Sci Transl Med 2014; 6: 236ra263.
23. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-289. doi: 10.1126/science.1178746 PMID: 19729618
24. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477: 466-470. doi: 10.1038/nature10373PMID: 21849977
25. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, dou-ble-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-1671. PMID: 17109337
26. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005; 64: 12.11.11-12.11.17.
27. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-1027.PMID: 7973652
28. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17: 1757-1765. PMID: 11788027
29. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science 2010; 329: 856-861. doi: 10.1126/science.1187659 PMID: 20616233
30. Ashkenazi A, Smith DH, Marsters SA, Riddle L, Gregory TJ, Ho DD, et al. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci U S A 1991; 88: 7056-7060. PMID: 1871120
31. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337: 525-531. PMID: 2536900
32. Schweighardt B, Liu Y, Huang W, Chappey C, Lie YS, Petropoulos CJ, et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007; 46: 1-11. PMID: 17514017
33. Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, et al. Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr 2010; 53: 36-46. doi: 10.1097/QAI.0b013e3181c4b885 PMID: 19910798
34. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44: 920-928. PMID: 10722492
35. Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, et al. Loss of aspara-gine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol 2011; 85: 3872-3880. doi: 10.1128/JVI. 02237-10 PMID: 21289125
36. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-575. PMID: 17116663
37. Clamp M, Cuff J, Searle SM, Barton GJ. The Jalview Java alignment editor. Bioinformatics 2004; 20: 426-427. PMID: 14960472
38. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 2008; 9: 286-298. doi: 10.1093/bib/bbn013 PMID: 18372315
39. DeLano WL. The PyMOL Molecular Graphics System. DeLano Scientific LLC, Palo Alto, CA USA; 2002.
40. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83: 7337-7348. doi: 10.1128/JVI.00110-09 PMID: 19439467
41. Vartanian JP, Henry M, Wain-Hobson S. Sustained G->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J Gen Virol 2002; 83: 801-805. PMID: 11907329
42. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242: 1171-1173. PMID: 2460925
43. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094. PMID: 7541846
44. Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr 1989; 2: 344-352. PMID: 2754611
45. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. Selection, recombination, and G-A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991; 65: 1779-1788. PMID: 2002543
46. Daar ES, Li XL, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 1990; 87: 6574-6578. PMID: 2395859
47. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, et al. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01-AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect 2009; 11: 334-343. doi: 10.1016/j.micinf.2008.12.008 PMID: 19136072
48. Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, et al. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1CRF01-AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J Virol 2010; 84: 4311-4320. doi: 10.1128/JVI. 02619-09 PMID: 20164234
49. Zwick MB, Burton DR. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 2007; 5: 608-624. PMID: 18045117
50. Katoh K, Toh H. Parallelization of the MAFFT multiple sequence alignment program. Bioinformatics 2010; 26: 1899-1900. doi: 10.1093/bioinformatics/btq224 PMID: 20427515
51. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, et al. Tracking global patterns of Nlinked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004; 14: 1229-1246. PMID: 15175256
52. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-10382. PMID: 2355006
53. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220. doi: 10.1056/NEJMoa0908492 PMID: 19843557
54. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004; 78: 5205-5215. PMID: 15113902
55. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, et al. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 2005; 79: 9069-9080. PMID: 15994801
56. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011; 203: 1165-1173. doi: 10.1093/infdis/jiq175 PMID: 21451004
57. Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998; 72: 7840-7845. PMID: 9733820
58. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003; 77: 2310-2320. PMID: 12551968
59. Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 2008; 372: 273-290.PMID: 18061231
60. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14 Suppl 3: S277-289. PMID: 9814956
61. Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999; 265: 1-9. PMID: 10603312
62. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191: 654-665.PMID: 15688278
63. Yu B, Morales JF, O'Rourke SM, Tatsuno GP, Berman PW. Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials. PLoS One 2012; 7: e43903. doi: 10.1371/journal. pone.0043903 PMID: 22928048
64. Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R, et al. HIV-1 Envelope Proteins and V1/V2 Domain Scaffolds with Mannose-5 to Improve the Magnitude and Quality of Protective Antibody Responses to HIV-1. J Biol Chem 2014; 289: 20526-20542. PMID: 24872420
65. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, et al. Evolution of an HIV gly-can-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012; 18: 1688-1692. doi: 10.1038/nm.2985 PMID: 23086475
66. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303: 2019-2022. PMID: 15044802
67. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79: 6528-6531. PMID: 15858037
68. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80: 9586-9598. PMID: 16973562